Skip to main content
OpenTrials
Completed

NCT Number: NCT03082339

Cortisone and QTc-Interval

Scientific and clinical data report about shortening of QTc-interval in patients treated with cortisone. Peal et al. analyzed chemical suppression of long QT syndrome (Type 2) in an in vivo zebrafish model. Their study revealed that flurandrenolide reproducibly suppressed the long QT phenotype via the glucocorticoid signaling pathway. In contrast to treatment with dexamethasone and testosterone, treatment with pure mineralocorticoid deoxycorticosterone acetate did not suppress long QT phenotype. Knockdown of the glucocorticoid receptor or, conversely, of the androgen receptor showed that flurandrenolide acting through the glucocorticoid receptor shortens ventricular action potentials. The mechanism is distinct from trafficking rescue of the defective zebrafish-ERG channel. The authors discuss that a drug normalizing repolarization would be a novel therapeutic tool in long QT syndrome and conclude that glucocorticoids could be expected to aid in the acute management of patients with long QT syndrome, e.g. in episodes of arrhythmic storm. In addition, corticoid induced normalization of the QT interval is reported in a patient with drug-induced prolongation of the QTc interval. Brostoff et al. report on a patient suffering from mucocutaneous leishmaniasis treated with sodium stibogluconate. During therapy, the QTc interval prolonged and returned to normal within 4 days after starting glucocorticoid therapy with prednisolone 20 mg twice daily.

Interrogation of the study:

* shortens cortisone the QTc-interval? * how long is the interval until shortening of QTc-interval? * is the effect prolonged? * is the effect dose dependend?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Giessen, Giessen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients who underwent therapy with cortisone (>=40mg/d)

Exclusion criteria

  • patients with elevated intracranial pressure
  • myocardial infarction within the last 6 months
  • untreated stenosis of the coronary arteries
  • right bundle branch block
  • autoimmune disease

Treatment and study plan

Cortisone

Other

Observation of QTc-interval

Primary outcomes

  1. Duration of QTc-interval

    Time frame: 1 week

    daily ECG controls and measuring QTc-interval

Sponsors and collaborators

Lead sponsor

Asklepios Neurological Clinic Bad Salzhausen

Other

Collaborators

  • University of Giessen

Registry information

Official study title

Influence of Cortisone on QTc-interval

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Mar 17, 2017
Registry last updated
May 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.